PUTHENPARAMPIL, MARCO
 Distribuzione geografica
Continente #
NA - Nord America 2.015
EU - Europa 271
AS - Asia 137
SA - Sud America 2
OC - Oceania 1
Totale 2.426
Nazione #
US - Stati Uniti d'America 2.011
IT - Italia 148
CN - Cina 108
SE - Svezia 35
GB - Regno Unito 28
FI - Finlandia 17
DE - Germania 16
VN - Vietnam 15
IN - India 11
UA - Ucraina 8
IE - Irlanda 5
FR - Francia 3
PL - Polonia 3
PR - Porto Rico 3
CH - Svizzera 2
ES - Italia 2
IR - Iran 2
NL - Olanda 2
BG - Bulgaria 1
BR - Brasile 1
HN - Honduras 1
JO - Giordania 1
NZ - Nuova Zelanda 1
RU - Federazione Russa 1
UY - Uruguay 1
Totale 2.426
Città #
Fairfield 375
Woodbridge 210
Ashburn 202
Chandler 177
Cambridge 145
Houston 126
Seattle 113
Wilmington 111
Ann Arbor 100
Padova 53
Beijing 36
San Diego 35
Princeton 31
Medford 29
Des Moines 21
Roxbury 18
Dong Ket 15
Los Angeles 15
Norwalk 15
Jacksonville 13
Milan 13
Boardman 10
London 10
Nanjing 10
Helsinki 9
New York 9
Nanchang 8
Rome 8
Grignasco 6
Dublin 5
Guangzhou 5
Washington 5
Brendola 4
Cagliari 4
Hefei 4
Ogden 4
Battaglia Terme 3
Borås 3
Jiaxing 3
Juana Diaz 3
Kunming 3
Mondolfo 3
Shenyang 3
Turin 3
Venice 3
Verona 3
Albignasego 2
Amsterdam 2
Bergheim 2
Bologna 2
Boston 2
Genoa 2
Hebei 2
Jinan 2
Kashan 2
Lappeenranta 2
Latina 2
Ravenna 2
Reggio Nell'emilia 2
Revere 2
Rovato 2
Rovigo 2
Strawczyn 2
Tianjin 2
Vasto 2
Vicenza 2
Zurich 2
Acton 1
Alessandria 1
Amman 1
Baotou 1
Barcelona 1
Caserta 1
Changsha 1
Chicago 1
Chiswick 1
Cinisello Balsamo 1
Esslingen am Neckar 1
Forlì 1
Fuzhou 1
Gualtieri 1
Hangzhou 1
Hounslow 1
Hérouville-saint-clair 1
Kharkiv 1
Kilburn 1
Labico 1
Leawood 1
Legnaro 1
Limana 1
Montevideo 1
Ningbo 1
Paris 1
Parma 1
Phoenix 1
Pinehaven 1
Prescot 1
Pune 1
Radeberg 1
Redwood City 1
Totale 2.059
Nome #
BAFF Index and CXCL13 levels in the cerebrospinal fluid associate respectively with intrathecal IgG synthesis and cortical atrophy in multiple sclerosis at clinical onset 129
Decreased platelet number in multiple sclerosis during alemtuzumab infusion: A common, transient and clinically silent phenomenon 125
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset 116
Cortical relapses in multiple sclerosis 115
Evidence of B-cell dysregulation in severe CNS inflammation after alemtuzumab therapy 112
Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination 109
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis. 108
Designing a Self-Perception Cognitive Questionnaire for Italian Multiple Sclerosis Patients (Sclerosi Multipla Autovalutazione Cognitiva, SMAC). A Preliminary Exploratory Pilot Study 99
Cerebrospinal fluid IL-1β correlates with cortical pathology load in multiple sclerosis at clinical onset 97
Cortical lesions and cognitive impairment in multiple sclerosis. 92
Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease 92
Acute simultaneous development of brain tumour–like lesion and demyelinating polyneuropathy in a patient with chronic relapsing myelitis 89
Hyperreflective Foci in the Retina of Active Relapse-Onset Multiple Sclerosis 87
PM2.5 levels strongly associate with multiple sclerosis prevalence in the Province of Padua, Veneto Region, North-East Italy 78
Free light chains in cerebrospinal fluid of multiple sclerosis patients negative for IgG oligoclonal bands 76
BAFF is decreased in the cerebrospinal fluid of multiple sclerosis at clinical onset 75
Trans-synaptic degeneration in the optic pathway. A study in clinically isolated syndrome and early relapsing-remitting multiple sclerosis with or without optic neuritis 74
Increased incidence of multiple sclerosis in the Veneto region, Italy. 73
A new T2 lesion in a patient with the clinically isolated syndrome does not necessarily imply a conversion to multiple sclerosis 73
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis 65
Wide Cytokine Analysis in Cerebrospinal Fluid at Diagnosis Identified CCL-3 as a Possible Prognostic Factor for Multiple Sclerosis 65
D-KEFS ST failure identifies multiple sclerosis patients with worse objective and self-perceived physical and cognitive disability 63
Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient 62
Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965-2018 58
Oligoclonal IgG bands in chronic inflammatory polyradiculoneuropathies 48
Association of Multiple Sclerosis with PM 2.5 levels. Further evidence from the highly polluted area of Padua Province, Italy 36
Encephalopathy as unique manifestation of Sjogren's syndrome: Expanding the spectrum of steroid-responsive encephalopathy 31
Posterior reversible encephalopathy syndrome: an atypical neurological manifestation of SARS-CoV-2 infection 31
Retinal Hyperreflecting Foci Associate With Cortical Pathology in Multiple Sclerosis 24
Validation of SMAC: normative data in the Italian population 16
Hyper-Reflecting Foci in Multiple Sclerosis Retina Associate With Macrophage/Microglia-Derived Cytokines in Cerebrospinal Fluid 15
Retinal inner nuclear layer thinning is decreased and associates with the clinical outcome in ocrelizumab-treated primary progressive multiple sclerosis 14
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis 14
Multiple sclerosis epidemiological trends in Italy highlight the environmental risk factors 13
Sars-CoV2 infection in pregnant women with multiple sclerosis 10
Case Report: Para-infectious cranial nerve palsy after bacterial meningitis 10
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD 9
Characterization of Antigen-Induced CD4+ T-Cell Senescence in Multiple Sclerosis 9
Clinical Profiles in Multiple Sclerosis: Cognitive Reserve and Motor Impairment along Disease Duration 9
Alemtuzumab as rescue therapy in case of multiple sclerosis rebound following Natalizumab break: Clinical case and literature review 9
Profili clinici nella Sclerosi Multipla: riserva cognitiva e compromissione motoria lungo il decorso della malattia. 9
Trans-synaptic degeneration in the optic pathway: Exploring the role of lateral geniculate nucleus in early stages of relapsing-remitting multiple sclerosis 8
Brain Citrullination Patterns and T Cell Reactivity of Cerebrospinal Fluid-Derived CD4+ T Cells in Multiple Sclerosis 7
Altered CSF Albumin Quotient Links Peripheral Inflammation and Brain Damage in MS 7
Blood-brain barrier damage associates with glia-related cytokines in the cerebrospinal fluid of patients with Multiple Sclerosis 6
Bruton tyrosine kinase inhibitors: can they be optimized for the treatment of neuroinflammatory disorders? 5
Sexual Dysfunction in Multiple Sclerosis: The Role of Executive Function 5
Alemtuzumab following natalizumab is more effective in adult-onset than paediatric-onset multiple sclerosis 3
No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study 2
Neurodegeneration in the retina of motoneuron diseases: a longitudinal study in amyotrophic lateral sclerosis and Kennedy’s disease 1
Totale 2.483
Categoria #
all - tutte 10.881
article - articoli 10.779
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 21.660


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019131 0 0 0 0 0 0 0 0 0 0 70 61
2019/2020532 51 28 33 59 49 30 49 61 55 52 39 26
2020/2021469 16 39 23 28 8 10 12 37 29 132 52 83
2021/2022428 13 14 45 33 31 53 20 46 17 30 33 93
2022/2023418 54 39 19 45 55 55 13 33 61 13 20 11
2023/2024320 12 43 47 37 36 48 31 24 14 24 4 0
Totale 2.483